Paving the way to improve therapy for Myeloproliferative Neoplasms.
Where this comes from
- Record sourced from PubMed, PMID 36028499.
- Also identified by DOI 10.1038/s41467-022-32694-2 and PMC identifier 9418146.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Long-acting IFNα induces durable molecular responses in myeloproliferative neoplasms. Emerging studies, including Saleiro et al. recently published in <i>Nature Communications</i>, have identified promising candidates that may synergise with IFNα by targeting stem cell function or feedback loops that mediate treatment resistance.
Medical subject headings
- Myeloproliferative Disorders
- Neoplasms